Silk Road Medical, Inc
Silk Road Medical, Inc., a pioneering medical device company headquartered in the United States, focuses on innovative solutions for carotid artery disease. Founded in 2007, the company has made significant strides in the vascular intervention industry, particularly with its flagship product, the ENROUTE Transcarotid Neuroprotection System. This unique system enhances patient safety during carotid artery procedures, setting Silk Road Medical apart in a competitive market. With a strong presence in North America and expanding operations in Europe, Silk Road Medical has established itself as a leader in the field of neuroprotection and minimally invasive vascular interventions. The company’s commitment to advancing patient care is reflected in its notable achievements, including FDA approvals and recognition for its contributions to improving surgical outcomes.
DitchCarbon Score
How does Silk Road Medical, Inc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Silk Road Medical, Inc's score of 68 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Silk Road Medical, Inc's reported carbon emissions
In 2023, Silk Road Medical, Inc. reported total greenhouse gas emissions of approximately 205,000 kg CO2e for Scope 1 and about 587,900 kg CO2e for Scope 2, resulting in a combined total of approximately 792,900 kg CO2e. This data reflects their global emissions, with no reported Scope 3 emissions. Comparatively, in 2022, the company recorded approximately 290,000 kg CO2e for Scope 1 and about 601,000 kg CO2e for Scope 2, leading to a total of around 891,000 kg CO2e. This indicates a reduction of about 98,100 kg CO2e in total emissions from 2022 to 2023. Silk Road Medical, Inc. is a current subsidiary of Boston Scientific Corporation, which influences its climate commitments and reporting. However, there are no specific reduction targets or climate pledges disclosed by Silk Road Medical, Inc. at this time. The company has not reported any initiatives under the Science Based Targets initiative (SBTi) or other climate frameworks, indicating a potential area for future development in their sustainability strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 275,000 | 000,000 | 000,000 |
| Scope 2 | 525,500 | 000,000 | 000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Silk Road Medical, Inc is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
